CDC Just Forecast a $15 Million Chronic Disease Education Competition — With a $375,000 Ceiling and a One-Disease-Only Rule

Nonprofit executive directors running disease-specific education programs got a $15 million planning signal on October 9, when CDC posted the forecast for Chronic Disease Education and Awareness (CDC-RFA-DP-27-0068) to grants.gov: roughly ten cooperative agreements, a $375,000 award ceiling, applications estimated due April 30, 2027.

That is seven months of runway on a competition that has not formally opened yet. The full notice of funding opportunity is not expected to post until March 1, 2027. What exists today is a forecast record — and for this particular program, the forecast is more useful than most, because CDC put the disqualifying rules in the forecast instead of saving them for the NOFO.

The $15 Million Headline Is Almost Certainly a Four-Year Number

The grants.gov forecast for CDC-RFA-DP-27-0068 lists estimated total program funding of $15,000,000 and an expected ten awards. Read quickly, that looks like $1.5 million per recipient. It is not.

Buried in the eligibility text is the real award band: "The award ceiling for this NOFO is $375,000. CDC will consider any application requesting an award higher than this amount non-responsive." The floor is $325,000, enforced the same way. So the arithmetic that reconciles the two figures is annual: ten awards at the $375,000 ceiling is $3.75 million per budget period, and four budget periods is exactly $15 million. With an estimated project start of September 30, 2027, a four-year period of performance running through 2031 is the reading the numbers support. CDC has not published the project period length yet, so treat that as inference — but budget as though you are competing for roughly $350,000 a year, not a seven-figure lump.

The mechanism is a cooperative agreement under Assistance Listing 93.945, Assistance Programs for Chronic Disease Prevention and Control, administered by CDC's National Center for Chronic Disease Prevention and Health Promotion. Cooperative agreement, not grant, matters operationally: CDC project officers participate substantively in the work, which means your staffing plan needs someone whose calendar can absorb federal programmatic involvement, not just reporting deadlines. There is no cost-sharing or matching requirement.

Three Ways to Get Disqualified Before a Reviewer Reads Your Narrative

Most forecast records say almost nothing about eligibility. This one spells out three non-responsiveness triggers, each of which kills an application outright.

One disease, not a portfolio. CDC will not consider any application proposing "more than a single chronic disease to focus on during the life of the cooperative agreement." For an ED whose organization covers a cluster of related conditions, this is the hardest constraint in the announcement. You will have to pick one and build the entire logic model around it.

It has to meet CDC's definition. The agency defines chronic disease broadly — "a condition that lasts 1 year or more and requires ongoing medical attention or limits activities of daily living or both" — but the definition is a gate, and an application proposing something outside it gets no further review.

It cannot already have a federal funding line. This is the exclusion that determines who can realistically compete. CDC names arthritis, heart disease, cancer, stroke, Alzheimer's disease and related dementias, diabetes, epilepsy, lupus, and chronic kidney disease — plus "any other chronic disease with a dedicated funding line in the FY 2027 Appropriations Act, as described on CDC's FY 2027 operating budget plan." If your condition has its own appropriation, you are categorically out of this competition and should be chasing the disease-specific NOFO instead.

The procedural requirement attached to all three is small and easy to fumble: applicants must upload a statement naming their proposed chronic disease as a PDF under miscellaneous attachments, filed as "Proposed Chronic Disease." A misfiled attachment on a competition with explicit non-responsiveness rules is not a correctable oversight.

Eligibility is otherwise unusually wide. Both 501(c)(3) and non-501(c)(3) nonprofits qualify, alongside state, county, city, and special district governments, federally recognized tribal governments and other tribal organizations, public and private institutions of higher education, independent school districts, public housing authorities, small businesses, and other for-profits. Bona fide agents are eligible, which means a smaller patient-advocacy organization can route the award through an administrative partner rather than standing up federal grants-management capacity it does not have.

The Ten Incumbents All Run Out of Money in 2027

The "ten awards" figure is not arbitrary. CDC currently funds exactly ten projects across two Chronic Disease Education and Awareness cohorts, and both cohorts end in 2027.

The Building Capacity cohort, a four-year award running 2023–2027, funds four recipients: the National Eczema Association on atopic dermatitis, Vermont's Agency of Human Services on COPD, the Board of Regents of the University of Oklahoma Health Sciences Center on chronic venous thromboembolism, and the Global Healthy Living Foundation on polymyalgia rheumatica.

The Expanding the National Approach cohort, a three-year award running 2024–2027, funds six: Food Allergy Research and Education on adult food allergies, the National Alliance for Hispanic Health on chronic liver disease, the American College of Chest Physicians on idiopathic pulmonary fibrosis, the Bone Health and Osteoporosis Foundation on osteoporosis, the National Psoriasis Foundation on psoriasis, and the National Association for Continence on urinary incontinence.

Four plus six is ten. DP-27-0068 is a recompete of the whole portfolio in a single competition, which tells you two things. First, the incumbents will almost all apply, and they will arrive with four years of CDC-reviewed performance data and established project officer relationships. Second, the conditions already covered are effectively spoken for — not by rule, but by the practical reality that a reviewer comparing your osteoporosis proposal to the Bone Health and Osteoporosis Foundation's renewal is making an easy call. The open lane is a condition nobody in that list of ten is working on.

That list of ten also calibrates what CDC thinks this work costs. The National Psoriasis Foundation's prior CDC cooperative agreement, NU58DP007060, obligated $1,029,742 across a three-year period beginning September 30, 2021 — about $343,000 a year, landing squarely inside the $325,000–$375,000 band CDC is now enforcing as a hard range. The dollar figure has not moved in six years. Neither has the scope expectation: surveillance data review and dissemination, developing or refining survey tools, producing educational resources for public health professionals, clinicians, and the public, and building partnerships that extend the reach of evidence-based information.

Why the Forecast, Not the March NOFO, Is the Real Decision Point

A seven-month gap between forecast and NOFO reads like slack. It is not. Everything that makes an application competitive on this particular opportunity has to happen before March 1, because the March document will add scoring criteria and page limits — it will not change which disease you picked, whether you have surveillance data worth disseminating, or whether a national clinical society has agreed to co-brand your materials.

This is the same structural trap we wrote about in Western SARE's two-stage funnel, where the pre-proposal, not the full proposal, is where the competition is actually decided. Here the gate is self-imposed rather than administrative, but the effect is identical: by the time the official document lands, the organizations that will win have already built the thing the document asks them to describe.

The concrete pre-March work is short and specific. Confirm your condition is not on CDC's FY 2027 dedicated-funding-line list, and check it against the published FY 2027 operating budget plan rather than assuming. Identify what surveillance data exists for it — BRFSS modules, NHANES, claims analyses, registry data — because "address priority evidence gaps" is a stated program outcome and you cannot credibly propose to close a gap you have not characterized. Get partnership commitments in writing from the professional societies and clinician networks that will carry your materials. And if you plan to use a bona fide agent, start that negotiation now; administrative partner agreements routinely take longer than the 60 days a NOFO window allows.

CDC lists Dr. Machell Town as the program contact at dphnofos@cdc.gov. Forecast-stage questions are generally fair game, and a short email confirming whether your condition clears the dedicated-funding-line exclusion is worth sending before you invest a quarter in positioning.

One timing caveat worth holding loosely: every date in this record is estimated. CDC posted DP-27-0068 on October 9 alongside a broader FY 2027 NCCDPHP forecast batch — cancer prevention programs for state, territorial, and tribal organizations (DP-27-0023), statewide perinatal quality collaboratives (DP-27-0043), national breastfeeding support (DP-27-0063), alcohol epidemiology capacity (DP-27-0072), and cancer surveillance workforce (DP-27-0076). FY 2027 appropriations will shape all of them. The estimated award date of August 31, 2027 and project start of September 30, 2027 sit right at the fiscal year boundary, which is where federal timelines slip. Plan for April 30, verify in March.

Next step: Search active chronic disease and health education solicitations on Granted to see what is open now while DP-27-0068 sits in forecast — and to find the disease-specific CDC lines you should be pursuing instead if your condition turns out to be excluded.